Previous Article | Next Article ![]()
Infection and Immunity, June 2006, p. 3222-3231, Vol. 74, No. 6
0019-9567/06/$08.00+0 doi:10.1128/IAI.00928-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
H:S Blodbank KI2033, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark,1 Department of Pharmacology, The Danish University of Pharmaceutical Sciences, DK-2100, Copenhagen, Denmark,2 Laboratoire de Parasitologie Biomedicale, Institut Pasteur, 28 rue du Dr. Roux, 75724 Paris Cedex 15, France3
Received 17 June 2005/ Returned for modification 28 July 2005/ Accepted 27 February 2006
Immunoglobulins from individuals with immunity to malaria have a strong antiparasitic effect when transferred to Plasmodium falciparum malaria infected patients. One prominent target of antiparasitic antibodies is the merozoite surface antigen 3 (MSP-3). We have investigated the antibody response against MSP-3 residues 194 to 257 (MSP-3194-257) on the molecular level. mRNA from peripheral blood leukocytes from clinically immune individuals was used as a source of Fab (fragment antibody) genes. A Fab-phage display library was made, and three distinct antibodies designated RAM1, RAM2, and RAM3 were isolated by panning. Immunoglobulin G1 (IgG1) and IgG3 full-length antibodies have been produced in CHO cells. Reactivity with the native parasite protein was demonstrated by immunofluorescence microscopy, flow cytometry, and immunoblotting. Furthermore, the antiparasitic effect of RAM1 has been tested in vitro in an antibody-dependent cellular inhibition (ADCI) assay. Both the IgG1 and the IgG3 versions of the antibody show an inhibitory effect on parasite growth.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|